Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5834973 | 0.80 | GHSR (0.68) | GHSRTSHRKCNH2LMNAHTT | |
| SCHEMBL5835625 | 0.76 | GHSR (1.00) | GHSRMAPTKCNH2 | |
| SCHEMBL5836504 | 0.76 | GHSR (1.00) | GHSRMAPTKCNH2 | |
| SCHEMBL5835834 | 0.69 | GHSR (0.54) | GHSRKCNH2DRD2 | |
| SCHEMBL5835214 | 0.68 | GHSR (0.53) | GHSRSMN1; SMN2MAPTKCNH2MEN1 | |
| SCHEMBL5835880 | 0.67 | GHSR (0.52) | GHSR | |
| SCHEMBL5835173 | 0.66 | GHSR (0.81) | GHSRSMN1; SMN2MAPTKCNH2L3MBTL1 | |
| SCHEMBL5835065 | 0.66 | GHSR (0.80) | GHSRSMN1; SMN2MAPTTSHRKCNH2 | |
| SCHEMBL5835274 | 0.66 | GHSR (0.65) | GHSRDRD2LMNA | |
| SCHEMBL5836521 | 0.65 | GHSR (0.64) | GHSRSMN1; SMN2TSHRDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115767-B2 | Tetraline derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | ABBVIE INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | GPR119, GHSR, GIPR | GHSR 2/4885SMN1; SMN2 2106/4885MAPT 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.